# Lyell Immunopharma

推进下一代 CAR 与 TCR-T 细胞疗法的临床后期公司，2026 年 6 月更新了 LYL273 在复发实体瘤中的安全性；其表观遗传重编程技术针对 T 细胞耗竭——实体瘤细胞治疗的核心障碍。

Source: https://cn.bioecon.ru/companies/lyell-immunopharma/
Updated: 2026-07-11

- 国家: United States
- 代码: LYEL

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 2026年3月完成$5000万股权私募配售交割 | https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-acquires-exclusive-global-rights-next, https://ir.lyell.com/node/9136/pdf, https://www.globenewswire.com/news-release/2026/08/06/3340726/0/en/Lyell-Immunopharma-Reports-Business-Highlights-and-Financial-Results-for-the-Second-Quarter-2026.html, https://www.sec.gov/Archives/edgar/data/1806952/000162828026017244/lyel-20260312x8kexx991.htm |
| 产能 | 每年生产超过1,200剂CAR T细胞 | https://ir.lyell.com/static-files/bddca8f8-1778-4048-8112-880812b9e93c, https://www.biospace.com/press-releases/lyell-immunopharma-provides-update-on-safety-profile-of-lyl273-in-relapsed-or-refractory-metastatic-colorectal-cancer-and-amends-phase-1-trial-to-phase-1-2-expansion, https://www.stocktitan.net/sec-filings/LYEL/10-k-lyell-immunopharma-inc-files-annual-report-04421e18ea60.html |
| 监管批准 | LYL273 用于治疗 mCRC 获快速通道认定 | https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-acquires-exclusive-global-rights-next, https://www.biospace.com/press-releases/lyell-immunopharma-provides-update-on-safety-profile-of-lyl273-in-relapsed-or-refractory-metastatic-colorectal-cancer-and-amends-phase-1-trial-to-phase-1-2-expansion, https://www.sec.gov/Archives/edgar/data/1806952/000162828026017244/lyel-20260312x8kexx991.htm, https://www.stocktitan.net/sec-filings/LYEL/10-k-lyell-immunopharma-inc-files-annual-report-04421e18ea60.html |
| 监管批准 | ronde-cel针对复发/难治性LBCL获得RMAT和Fast Track资格认定 | https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-reports-business-highlights-and-financial-10, https://www.biospace.com/press-releases/lyell-immunopharma-provides-update-on-safety-profile-of-lyl273-in-relapsed-or-refractory-metastatic-colorectal-cancer-and-amends-phase-1-trial-to-phase-1-2-expansion, https://www.sec.gov/Archives/edgar/data/1806952/000162828026017244/lyel-20260312x8kexx991.htm |
| 生产基地 | 位于华盛顿州博塞尔（Bothell）的LyFE Manufacturing Center（LyFE） | https://ir.lyell.com/static-files/bddca8f8-1778-4048-8112-880812b9e93c, https://www.stocktitan.net/sec-filings/LYEL/10-k-lyell-immunopharma-inc-files-annual-report-04421e18ea60.html |
| 营收 | 2025全年为$36,000 | https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-reports-q4-and-full-year-2025-business-and, https://www.globenewswire.com/news-release/2026/08/06/3340726/0/en/Lyell-Immunopharma-Reports-Business-Highlights-and-Financial-Results-for-the-Second-Quarter-2026.html, https://www.tickergate.com/stocks/lyel/revenue |

独立来源: biospace.com, globenewswire.com, ir.lyell.com, sec.gov, stocktitan.net, tickergate.com

## 技术

- [TCR 疗法（T 细胞受体工程化 T 细胞）](https://cn.bioecon.ru/technology/tcr-therapy/)